. "# Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E: Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):477-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16634115"@en . . . . . . . . . . . . . . . . . . . . . "5-chloro-N-(2-(4-((((Cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide"@en . "Humans and other mammals"@en . "1-(P-(2-(5-chloro-2-Methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "10238-21-8"@en . . "Glibenclamidum"@en . . . . "1-((P-(2-(5-chloro-O-Anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea"@en . . . . . . . . "Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine."@en . . . . "Glynase"@en . . . . "Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone."@en . "Steady state V_d=0.125 L/kg; V_d during elimination phase=0.155 L/kg."@en . "Take 30-60 minutes before breakfast."@en . "Sulfonylureas such as glyburide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin."@en . . . . . . . . . "Unchanged drug is ~99% bound to serum proteins; 4-trans-hydroxyglyburide is greater than 97% bound to serum proteins. Protein binding is primarily nonionic making glyburide and is less likely to displace or be displaced by drugs that bind via an ionic mechanism. "@en . . . . "1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. "@en . . . . . . . . . . "Micronase"@en . . . "Suresh Gidwani, \"Solid oral dosage form of metformin and glyburide and the method of preparation thereof.\" U.S. Patent US20040175421, issued September 09, 2004."@en . . . . . . . . . . . . . " "@en . . . . . . . . . . . . . . . "Glibenclamida"@en . . . . . . . . . . . . . . . "78 ml/hr/kg in healthy adults. Clearance may be substantially decreased in those with severe renal impairment. "@en . . . . "Glyburide"@en . . . . . . "Diabeta"@en . "Significant absorption within 1 hour and peak plasma levels are reached in 2 to 4 hours. Onset of action occurs within one hour. "@en . . . "Avoid alcohol."@en . . . . . . . . . "Glibenclamide"@en . . "Glyburide"@en . "Glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide's hypoglycemic effect is thought to be clinically unimportant. Glyburide metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m². "@en . "approved"@en . . "Oral rat LD₅₀: > 20,000 mg/kg. Oral mouse LD₅₀: 3250 mg/kg."@en . . . . .